4/16
02:17 pm
clym
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway [Seeking Alpha]
Low
Report
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway [Seeking Alpha]
4/16
06:14 am
clym
Climb Bio (CLYM) was upgraded by Mizuho to "strong-buy".
Low
Report
Climb Bio (CLYM) was upgraded by Mizuho to "strong-buy".
4/15
07:00 am
clym
Climb Bio (CLYM) was given a new $18.00 price target by Mizuho.
Medium
Report
Climb Bio (CLYM) was given a new $18.00 price target by Mizuho.
4/8
08:03 am
clym
Climb Bio (CLYM) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
Low
Report
Climb Bio (CLYM) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
4/8
07:00 am
clym
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Low
Report
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
4/7
07:00 am
clym
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Medium
Report
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
4/6
02:19 pm
clym
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight [Yahoo! Finance]
Low
Report
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight [Yahoo! Finance]
3/26
05:49 am
clym
Climb Bio (CLYM) was upgraded by B. Riley Financial, Inc. to "strong-buy".
Low
Report
Climb Bio (CLYM) was upgraded by B. Riley Financial, Inc. to "strong-buy".
3/24
09:00 am
clym
Climb Bio (CLYM) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Low
Report
Climb Bio (CLYM) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
3/19
06:20 am
clym
Climb Bio (CLYM) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Climb Bio (CLYM) was upgraded by Truist Financial Corporation to "strong-buy".
3/17
07:03 pm
clym
Climb Bio (CLYM) was given a new $17.00 price target by Truist Financial Corporation.
Low
Report
Climb Bio (CLYM) was given a new $17.00 price target by Truist Financial Corporation.
3/14
08:16 am
clym
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 [Yahoo! Finance]
Medium
Report
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 [Yahoo! Finance]
3/10
05:04 pm
clym
Climb Bio (CLYM) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Medium
Report
Climb Bio (CLYM) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
3/10
08:03 am
clym
Climb Bio (CLYM) had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Climb Bio (CLYM) had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a "buy" rating on the stock.
3/6
08:03 am
clym
Climb Bio (CLYM) had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
Climb Bio (CLYM) had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an "outperform" rating on the stock.
3/5
08:45 am
clym
Climb Bio (CLYM) is now covered by Wedbush. They set an "outperform" rating and a $12.00 price target on the stock.
Low
Report
Climb Bio (CLYM) is now covered by Wedbush. They set an "outperform" rating and a $12.00 price target on the stock.
3/5
07:15 am
clym
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/5
07:00 am
clym
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Low
Report
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2/13
07:01 am
clym
Climb Bio (NASDAQ:CLYM) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
Climb Bio (NASDAQ:CLYM) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
2/5
07:18 am
clym
Climb Bio to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Climb Bio to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/5
07:00 am
clym
Climb Bio to Present at Upcoming Investor Conferences
Medium
Report
Climb Bio to Present at Upcoming Investor Conferences
1/24
07:11 pm
clym
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate [Yahoo! Finance]